Illumina Stock Analysis (NASDAQ:ILMN)

Add to My Stocks
$170.58 $2.89 (1.72%) ILMN stock closing price Mar 24, 2017 (Closing)
Watch Robo Advisor Video of ILMN Stock Analysis
Illumina
Updated on : Mar 24, 2017
previous close
ILMN 170.6 (0%)
S&P 500 2344 (0%)
Closing Price On: Mar 24, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q4
$million
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
24.5%
Sector Average:
-6.4%
5 Quarter Net Profit
Net Margins
2016-Q4
%
LTM Margin
Compared to the industry
Debt/Equity Ratio
Debt:
1.27B
Debt/Equity Ratio:
 0.56
Compared to the industry
Cash Flow
Operating cash flow:
$280.2M
Net Income:
$123.9M
PROS      CONS
Operating Margins
Net Margins
Cash Flow
ROIC
ROE
FCF Margin
High Debt Burden
PE Valuation
PS Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
ILMN PS :
10.4
Industry PS :
4.7
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
22%
Return on Equity:
21.7%
Free Cash Flow Margin:
32.1%
Double Tap To Exit Full Screen
0:00
/

Illumina Analysis Video

436 6 2

View Illumina stock analysis video. This is our ILMN analyst opinion covering the buy and sell arguments for ILMN stock.

Illumina, Inc. Stock Rating (3.7/5)

Our Illumina stock opinion is based on fundamentals of the company. This Illumina stock analysis is based on latest Q4 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy ILMN stock?

  • The TTM operating margin was good at 24.5% for Illumina.
  • LTM Net margins were good at 19.3% for Illumina.
  • The operating cash flow looks good at 2.3 times the net income.
  • Illumina has an attractive ROIC (Return on Invested Capital) of 22%
  • The LTM ROE of 21.7% for Illumina is attractive.
  • The company has a good Free Cash Flow (FCF) margin of 32.1%.

Should you sell ILMN stock?

  • With a debt/equity ratio of  0.56, Illumina is highly leveraged in comparison to Medical peers.
  • The ILMN stock currently trades at a PE of 50.3, which is expensive, compared to the industry average of 21.
  • ILMN stock is trading at a PS multiple of 10.4, which is a negative when compared to the Medical-Biomed-Genetics industry average multiple of 4.7.

Comments on this video and Illumina stock